English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduSuzanne Bell, PhD, of the Johns Hopkins Bloomberg School of Public Health is available to comment on the safety of mifepristone and the impact of restricting access to it as the U.S. Supreme Court hears oral arguments in the Food…
Tag: Mifepristone
SCOTUS to Hear Mifepristone Case: American University Experts Comment
What: On Tuesday, March 26, the Supreme Court will hear a case that challenges the FDA’s approval of mifepristone, the FDA-approved medication used for medical abortion care (the most common abortion method in the U.S.). American University experts are available to comment on the implications…
Medication for abortion or miscarriage management unavailable at most Hamilton, Ontario pharmacies survey finds
A medication commonly used for abortion or miscarriage management is only available at six per cent of Hamilton, Ont. pharmacies, according to a McMaster University-led survey.
Bloomberg School Experts on Anniversary of Dobbs Decision Overturning Roe v. Wade
Two reproductive health and legal experts from the Johns Hopkins Bloomberg School of Public Health are available for comment about the upcoming one-year anniversary of Dobbs v. Jackson Women’s Health Organization (June 24), which overturned the U.S. Supreme Court’s landmark…
Endocrine Society alarmed by Texas court ruling banning mifepristone
The Endocrine Society is deeply concerned about a Texas ruling that reverses the U.S. Food and Drug Administration’s (FDA) approval of mifepristone, a drug used to treat Cushing’s syndrome and to end pregnancy safely and effectively.
Kacsmaryk’s Ruling on Abortion Pill is “Devastating And Unprecedented”
Statement from Suzanne Bell, an assistant professor in the Johns Hopkins Bloomberg School of Public Health’s Department of Population, Family and Reproductive Health, following the ruling from Judge Matthew J. Kacsmaryk in Amarillo, TX, that suspends the FDA’s approval of mifepristone.
Study shows family medicine physicians face many barriers to providing medical abortions
A study by UC Davis and UC San Francisco identified multiple barriers that family physicians navigate to provide abortion services to their patients. The barriers include lack of physician training and federal, state and institutional restrictions on providing medication abortion.
Study finds that physicians support pharmacy dispensing in order to expand access to medication abortion
Interviews with primary care providers showed support for removal of the FDA’s mifepristone Risk Evaluation and Mitigation Strategy, which prevents pharmacists from dispensing the drugs needed for medication abortions.